Quick Answer
Omega-3 Triglyceride Meta-Analysis has evidence relevant to safety, limits, and clinician-discussion contexts, but conclusions should stay close to the cited sources. One representative finding is: Background The rising global burden of metabolic dysfunction-associated steatotic liver disease (MASLD) necessitates effective therapies.
Key Takeaways
- 01Background The rising global burden of metabolic dysfunction-associated steatotic liver disease (MASLD) necessitates effective therapies. [Li L (2026)]
- 02Results Pooled data from 9 studies (n=528) revealed that omega-3 PUFA supplementation was associated with a significant reduction in triglyceride (TG) levels in MASLD patients (MD: -13.81 mg/dL; 95% CI: -24.56, -3.06); however, considerable heterogeneity (I²=22.5%) suggests that the true effect may be inconsistent across different patient populations. [Li L (2026)]
- 03Conclusion This meta-analysis suggests that omega-3 fatty acids are associated with reduced TG levels in MASLD patients on average, but the effect is inconsistent and influenced by diabetes status. [Li L (2026)]
- 04This meta-analysis therefore assesses the efficacy of omega-3 PUFAs in reducing triglycerides in MASLD patients and examines how diabetes status modulates this effect. [Li L (2026)]
The current Migaku evidence database contains 2 reusable source documents for Omega-3 Triglyceride Meta-Analysis. This answer focuses on safety, limits, and clinician-discussion contexts.
- Background The rising global burden of metabolic dysfunction-associated steatotic liver disease (MASLD) necessitates effective therapies. [Li L (2026); evidence level 1]
- Results Pooled data from 9 studies (n=528) revealed that omega-3 PUFA supplementation was associated with a significant reduction in triglyceride (TG) levels in MASLD patients (MD: -13.81 mg/dL; 95% CI: -24.56, -3.06); however, considerable heterogeneity (I²=22.5%) suggests that the true effect may be inconsistent across different patient populations. [Li L (2026); evidence level 1]
- Conclusion This meta-analysis suggests that omega-3 fatty acids are associated with reduced TG levels in MASLD patients on average, but the effect is inconsistent and influenced by diabetes status. [Li L (2026); evidence level 1]
- This meta-analysis therefore assesses the efficacy of omega-3 PUFAs in reducing triglycerides in MASLD patients and examines how diabetes status modulates this effect. [Li L (2026); evidence level 1]
- Molecular Mechanisms and Therapeutic Targets of RNA-Based and Traditional Lipid-Lowering Agents in Residual Cardiovascular Risk: A Scoping Review of Key Directions Towards Future Perspectives [Molecular Mechanisms and Therapeutic Targets of RNA-Based and Traditional Lipid-Lowering Agents in Residual Cardiovascular Risk: A Scoping Review of Key Directions Towards Future Perspectives (2026); evidence level 3]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources
- The Impact of Omega-3 Fatty Acids on Triglyceride Levels in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-Analysis of Randomized Controlled Trials with Subgroup Analysis by Diabetes Status.
- Molecular Mechanisms and Therapeutic Targets of RNA-Based and Traditional Lipid-Lowering Agents in Residual Cardiovascular Risk: A Scoping Review of Key Directions Towards Future Perspectives